RenovoRx(RNXT) - 2025 Q4 - Annual Results

Financial Performance - RenovoRx generated $1.1 million in revenue for the full year 2025, marking its first full year of RenovoCath commercialization, compared to $43,000 in 2024[16] - The net loss for 2025 was approximately $11.2 million, compared to a net loss of $8.8 million in 2024[20] - Selling, general, and administrative expenses increased to approximately $7.0 million in 2025, driven by the buildout of commercial infrastructure and higher personnel costs[19] - Research and development expenses for 2025 were approximately $6.3 million, reflecting continued investment in the Phase III TIGeR-PaC clinical trial and device development[18] - The company has $13 million in cash on hand as of March 2026, following a private placement that raised $10 million in gross proceeds[15] Clinical Trials and Product Development - The Phase III TIGeR-PaC trial is on track for full enrollment by mid-2026, with 104 patients randomized and 72 events observed as of March 24, 2026[4] - RenovoRx is evaluating its novel drug-device combination oncology product candidate, IAG, in the ongoing Phase III TIGeR-PaC trial[32] - IAG utilizes the patented RenovoCath device, which is FDA-cleared for temporary vessel occlusion in various applications[32] - The IAG combination product has received Orphan Drug Designation for pancreatic cancer and bile duct cancer, providing seven years of market exclusivity upon FDA approval[33] Market Potential - The initial total addressable market (TAM) for RenovoCath is estimated at approximately $400 million in peak annual U.S. sales, with potential for multi-billion-dollar expansion[7] - RenovoRx aims to transition 17 cancer centers using RenovoCath in the TIGeR-PaC trial to commercial customers in the second half of 2026[4] Strategic Initiatives - The company established a Medical Advisory Board in February 2026 to provide strategic clinical guidance for advancing the TAMP therapy platform[13] - RenovoRx's strategic plans include potential collaborations and partnerships to enhance product development[35] - The company is committed to maintaining and expanding its intellectual property rights related to its therapy platform and product candidates[35] Risks and Uncertainties - Forward-looking statements indicate potential risks and uncertainties related to clinical trials, commercialization efforts, and regulatory approvals[35] - The timing and results of clinical trials are uncertain and may not predict regulatory approval outcomes[35] - RenovoRx's ability to efficiently utilize cash resources and raise additional funding is critical for future operations[35] - The company emphasizes the importance of retaining key personnel and hiring qualified staff for future growth[35] Market Expansion - As of February 27, 2026, 12 U.S. cancer centers are actively utilizing RenovoCath, with an additional 21 centers evaluating or preparing for activation, tripling the near-term pipeline since Q1 2025[3]